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patients having access to the lower price Arsumax® increased
up to 38% of population buying Arsumax® at normal price
(3673 / 9641). During the same period, we notice no consump-
tion decrease for others antimalarials of the same therapeutic
group. Patients and pharmacists have strictly observed the
program procedures. CONCLUSION: This study shows that a
differentiated price policy allows efﬁcient access to high quality
antimalarial drugs for low-income population, through the
private drug distribution system. Moreover this program is
running without any ﬁnancing support from the government or
international funding. Based on this test, the program is being
implemented over the entire country and to other African 
countries.
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HPV is currently the most common sexually transmitted disease
in the United States. It is highly prevalent among sexually active
men and women, affecting 20 million people with 5.5 million
new cases occurring yearly. About 75% of sexually active indi-
viduals will acquire the infection at some point during their life-
time. The highest rates of genital HPV infection have consistently
been found in sexually active college age population (20–24-age
bracket). OBJECTIVES: To assess knowledge of HPV among
students attending an HBCU and to test the effectiveness of an
educational intervention program. METHOD: The participants
for this research project were 3rd year Pharm.D college students
enrolled at a HBCU in Florida. The design was repeated mea-
sures with an intervention versus control group. A general
knowledge HPV survey was administered to assess HPV knowl-
edge. T-tests were used to analyze the data. RESULTS: Eighty-
six percent of the population had heard of HPV. Knowledge of
HPV was generally low; out of 6 questions posed only 2 were
answered correctly by more than 70% of the population. Edu-
cation was effective in increasing knowledge of HPV [t(50) =
4.53, p = 0.000]. CONCLUSIONS: Awareness of HPV in this
population was high but knowledge was low. Simple educational
material is effective in increasing knowledge of HPV.
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OBJECTIVES: The primary objective of this analysis was to
identify factors associated with prolonged length of stay (LOS)
in patients with hospitalized community acquired pneumonia
(CAP). METHODS: Data were collected retrospectively on 1861
randomly selected patients with a discharge ICD-9 diagnosis of
CAP who were admitted between October 2000 and April 2003
to 29 hospitals in the Great Lakes region. A standardized elec-
tronic database was used to collect demographic and clinical
data. Logistic regression analysis was used to adjust for poten-
tial confounding variables and to identify patient factors associ-
ated with a LOS greater than 4 days (cohort median). Pneumonia
Severity Index Score (PSI) deﬁned risk class. Antibiotic selection
was evaluated relative to standard guidelines (Infectious Diseases
Society of America). RESULTS: Patient factors associated with
a LOS greater than 4 days included admission during the
2001–2002 season (OR, 1.35; 95% CI, 1.06–1.72), increasing
age (OR, 1.01; 95% CI, 1.00–1.02), Risk Class III (OR, 1.50;
95% CI, 1.10–2.06), Risk Class IV (OR, 1.67; 95% CI,
1.20–2.32), Risk Class V (OR, 3.01; 95% CI, 2.0–4.76), ICU
admission for pneumonia (OR, 2.11; 95% CI, 1.31–3.40), gram-
negative sputum culture (OR, 2.15; 95% CI, 1.37–3.38), gram-
positive blood culture (OR, 2.01; 95% CI, 1.28–3.17),
increasing hours to antibiotic administration (OR, 1.02; 95% CI,
1.01–1.04), modiﬁcation of empiric antibiotic regimen (OR,
1.45; 95% CI, 1.17–1.81) and intravenous to oral antibiotic con-
version (OR, 2.01; 95% CI, 1.63–2.48). Administration of
antibiotic regimens consistent with IDSA guidelines was associ-
ated with reduced odds for a longer LOS (OR, 0.50; 95% CI,
0.33–0.77). CONCLUSIONS: Several factors were associated
with a hospital LOS greater than 4 days. Guideline-compliant
antibiotic use was associated with reduced odds for a long LOS.
These ﬁndings may facilitate further research and the develop-
ment of targeted management strategies to control LOS and ulti-
mately resource consumption.
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OBJECTIVE: Clinical trials results are used to guide empiric
antifungal therapy. However, how subjects enrolled into clinical
trials compare to “real-world” patients is unclear. The purpose
of this study was to compare the inclusion/exclusion criteria
from published candidemia trials to hospitalized patients with
candidemia at our institution. METHODS: The inclusion/
exclusion criteria from two large, randomized trials of can-
didemia (N Eng J Med 1994;331:1325–30 and Clin Infect Dis
2003;36:1221–8) were assessed for 86 patients hospitalized 
with candidemia between 2002 to 2004 at our institution. 
Variables collected included APACHEII, vitals, receipt of anti-
fungals, past medical and hospitalization history including 
hematologic cancer, HIV, burns, allergy, organ transplantation,
previous candidemia and laboratory values including bilirubin
and liver function tests. Inclusion/exclusion criteria from the
published clinical trial were compared to results from our patient
population. Percent of patients that would be eligible for study
entry were calculated. RESULTS: Seventy-nine percent of our
patients would have been excluded from the clinical trials. 
The most common exclusion criteria included receipt of ampho-
tericin before identiﬁcation of candida (42%), laboratory abnor-
malities including elevated bilirubin (15%) and elevated
aminotransferases (2%), organ transplantation (8%) or HIV
(3%). No patients were excluded due to pregnancy, burns, 
allergies, other investigational agents, or congenital immun-
odeﬁciency syndrome. If it were possible to include patients
before receipt of antifungals, 51% of patient would have been
able to be enrolled in the study. ApacheII scores were similar 
in published clinical trials (16.1) compared to our patient pop-
ulation (17.3). CONCLUSION: Subjects enrolled into can-
didemia clinical trials were similar to our patient population
including severity of illness. Exclusion criteria generally involve
laboratory safety parameters or different patient populations.
Results from these clinical trials are applicable to “real-world”
patients.
